One Dipping Stock Hedge Funds Like and a Healthcare Company Smart Money is Not Bullish On

Page 2 of 2

Another stock that we would like to take a look at is Arrowhead Research Corp (NASDAQ:ARWR), which started the day in green and currently trades up by 11%. Earlier today, the biopharmaceutical company announced that it has nominated ARC-HIF2 as its first therapeutic candidate developed using Dynamic Polyconjugate, which is designed to target tissues outside of the liver. The company will present some preclinical results at the end of September.

The news might attract more attention to Arrowhead Research Corp (NASDAQ:ARWR) from hedge funds, but so far, the smart money has been cautious regarding the company and at the end of June nine investors disclosed holding $36.12 million worth of stock, equal to 8.50% of the company, down from 11 funds holding $63.68 million in aggregate. Moreover, during the second quarter, most of Arrowhead Research Corp (NASDAQ:ARWR)’s top shareholders in our database opted to reduce their exposure to the company. Among them, Israel Englander’s Millennium Management and Daniel Gold’s QVT Financial, reduced their positions by 4% and 24% to 2.14 million shares and 1.60 million shares respectively.

Disclosure: none

Page 2 of 2